NASDAQ:RNLX

Renalytix (RNLX) Stock Forecast, Price & News

$2.04

-0.14 (-6.42%)

(As of 06/9/2023 ET)

Compare

Today's Range: $1.86
▼
$2.13
50-Day Range: $2.04
▼
$2.52
52-Week Range: $1.05
▼
$5.00

Volume: 255,690 shs
Average Volume: 45,475 shs
Market Capitalization: $95.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Renalytix MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 120.6% Upside
$4.50 Price Target
Short Interest: Healthy
0.57% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.33
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.55) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Computer And Technology Sector

406th out of 600 stocks

Medical Laboratories Industry

15th out of 22 stocks

3.5

Analyst's Opinion

Consensus Rating
Renalytix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.50, Renalytix has a forecasted upside of 120.6% from its current price of $2.04.
Amount of Analyst Coverage
Renalytix has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.57% of the outstanding shares of Renalytix have been sold short.
Short Interest Ratio / Days to Cover
Renalytix has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Renalytix has recently decreased by 20.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Renalytix does not currently pay a dividend.
Dividend Growth
Renalytix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNLX.

0.9

News and Social Media Coverage

News Sentiment
Renalytix has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Renalytix this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Renalytix insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.60% of the stock of Renalytix is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.81% of the stock of Renalytix is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Renalytix are expected to decrease in the coming year, from ($0.55) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Renalytix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Renalytix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Renalytix has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Renalytix (NASDAQ:RNLX) Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Receive RNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RNLX Stock News Headlines

June 10, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Renalytix Plc (NASDAQ:RNLX) Decreased by HC Wainwright

June 9, 2023 | msn.com

Renalytix: Q3 Earnings Insights

June 10, 2023 | Vector Vest (Ad)

Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

June 8, 2023 | benzinga.com

Earnings Preview For Renalytix

June 8, 2023 | americanbankingnews.com

Renalytix (RNLX) Scheduled to Post Earnings on Friday

June 5, 2023 | finance.yahoo.com

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

May 30, 2023 | americanbankingnews.com

Renalytix Plc (NASDAQ:RNLX) Short Interest Update

May 25, 2023 | finance.yahoo.com

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

June 10, 2023 | Vector Vest (Ad)

Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

April 7, 2023 | americanbankingnews.com

Q3 2023 Earnings Forecast for Renalytix Plc (NASDAQ:RNLX) Issued By HC Wainwright

April 6, 2023 | finance.yahoo.com

Renalytix Plc (NASDAQ:RNLX) Q2 2023 Earnings Call Transcript

April 6, 2023 | americanbankingnews.com

HC Wainwright Cuts Renalytix (NASDAQ:RNLX) Price Target to $5.00

April 5, 2023 | americanbankingnews.com

Renalytix (NASDAQ:RNLX) Price Target Cut to $5.00

April 4, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Renalytix AI (RNLX)

April 3, 2023 | americanbankingnews.com

BTIG Research Trims Renalytix (NASDAQ:RNLX) Target Price to $3.50

March 22, 2023 | finance.yahoo.com

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

December 7, 2022 | finance.yahoo.com

Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript

November 22, 2022 | finance.yahoo.com

Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30

November 3, 2022 | finance.yahoo.com

Renalytix to Present at Stifel Healthcare Conference

October 31, 2022 | finance.yahoo.com

Renalytix Reports Full Year Fiscal 2022 Results

October 17, 2022 | globenewswire.com

KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology - GlobeNewswire

October 17, 2022 | finance.yahoo.com

KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology

October 2, 2022 | fool.co.uk

No savings at 35? I'd use the Warren Buffett method to build wealth - Motley Fool UK

September 20, 2022 | globenewswire.com

Renalytix Announces Change to Board of Directors - GlobeNewswire

September 8, 2022 | benzinga.com

Renalytix (NASDAQ:RNLX) – Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conferenc - Benzinga

September 8, 2022 | finance.yahoo.com

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022 | uk.finance.yahoo.com

Renalytix Plc (RNLX)

See More Headlines

RNLX Price History

30 days | 90 days | 365 days | Advanced Chart

RNLX Company Calendar

Last Earnings: 3/30/2023
Today: 6/10/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: NASDAQ:RNLX
CUSIP: N/A
CIK: 1811115
Web: www.renalytixai.com
Phone: 44-20-3139-2910
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.50
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $3.50
Forecasted Upside/Downside: +120.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,280,000.00
Net Margins: -1,411.70%
Pretax Margin: -1,109.91%
Return on Equity: -239.26%
Return on Assets: -128.09%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 1.86
Quick Ratio: 1.86

Sales & Book Value

Annual Sales: $3.80 million
Price / Sales: 25.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.82 per share
Price / Book: 2.49

Miscellaneous

Outstanding Shares: 46,891,000
Free Float: 36,763,000
Market Cap: $95.66 million
Optionable: Not Optionable
Beta: 2.47

Key Executives

Mr. James R. McCullough M.B.A. (Age 54)
CEO & Exec. Director
Comp: $648k

Mr. Fergus Fleming (Age 55)
CTO & Exec. Director
Comp: $449k

Mr. Thomas H. McLain CPA (Age 63)
M.B.A, Pres

Mr. Oliver James Sterling III
Chief Financial Officer

Ms. Andria Parks-Herrera
VP of Marketing

Ms. Jean M. Casner (Age 63)
Sr. VP & Chief HR Officer

Mr. Baljit Singh
Head of Clinical Operations

Dr. Michael J. Donovan M.D. (Age 68)
Ph.D., Chief Medical Officer

Mr. Salim Hamir F.C.A.
Company Sec.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RNLX Stock - Frequently Asked Questions

Should I buy or sell Renalytix stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RNLX shares.
View RNLX analyst ratings or view top-rated stocks.
What is Renalytix's stock price forecast for 2023?: 3 equities research analysts have issued 12 month target prices for Renalytix's stock. Their RNLX share price forecasts range from $3.50 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 120.6% from the stock's current price.
View analysts price targets for RNLX or view top-rated stocks among Wall Street analysts.
How have RNLX shares performed in 2023?: Renalytix's stock was trading at $1.87 at the beginning of 2023. Since then, RNLX stock has increased by 9.1% and is now trading at $2.04.
View the best growth stocks for 2023 here.
How were Renalytix's earnings last quarter?: Renalytix Plc (NASDAQ:RNLX) released its quarterly earnings data on Thursday, March, 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $1.19 million for the quarter, compared to analysts' expectations of $1.33 million. Renalytix had a negative trailing twelve-month return on equity of 239.26% and a negative net margin of 1,411.70%.
What other stocks do shareholders of Renalytix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).
When did Renalytix IPO?: (RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO.

What is Renalytix's stock symbol?: Renalytix trades on the NASDAQ under the ticker symbol "RNLX."
Who are Renalytix's major shareholders?: Renalytix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (2.09%), Pinnacle Associates Ltd. (1.72%), Tejara Capital Ltd (0.90%), Granahan Investment Management LLC (0.02%), Envestnet Asset Management Inc. (0.02%) and Simplex Trading LLC (0.00%).
How do I buy shares of Renalytix?: Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Renalytix's stock price today?: One share of RNLX stock can currently be purchased for approximately $2.04.
How much money does Renalytix make?: Renalytix (NASDAQ:RNLX) has a market capitalization of $95.66 million and generates $3.80 million in revenue each year. The company earns $-45,280,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
How can I contact Renalytix?: Renalytix's mailing address is AVON HOUSE 19 STANWELL ROAD PENARTH, CARDITH X0, CF64 2EZ. The official website for the company is www.renalytixai.com. The company can be reached via phone at 44-20-3139-2910 or via email at investors@renalytixai.com.

This page (NASDAQ:RNLX) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial